Can We Stem the Tide of Unsuccessful Drugs?

| February 11, 2019

article image
While an increasing number of drugs is being developed, fewer of them are approved yearly by the US Food and Drug Administration (FDA), compared to the 1990s.1 As of today, it can cost up to $ 2.6 billion for a drug to be developed over an average of 10 years.2 Pharmaceutical companies are acknowledging this problem and investigating ways to decrease this costly inefficiency. Could one solution lie with the use of pluripotent stem cells?

Spotlight

Merck Consumer Health Care

Merck is a global pharmaceutical and chemical company with a history that began in 1668, and a future shaped by around 40,000 employees in 64 countries. With the acquisition of Millipore in July 2010, a global leader in the life science tools market, pro forma revenues totaled around EUR 8.9 billion in 2009. Innovations made possible by entrepreneurial employees characterize the company’s success. Merck's operating activities are combined under the umbrella of Merck KGaA, in which the Merck family indirectly holds an interest of approximately 70%. The remaining 30% is publicly traded.

OTHER ARTICLES

Five Ways to Manage Your Trial Effectively in a Fast-Changing Global Environment

Article | March 11, 2020

Over the past half-century, clinical trials have grown increasingly complex. A flood of new data from novel sources combined with more elaborate study designs and tougher regulatory standards have lengthened timelines and hiked costs, contributing to a steady decline of efficiency. It all adds up: Nearly half of all drug launches underperform revenue expectations. And if that isn’t enough, the outbreak of COVID-19 worldwide is having an effect on how life sciences companies operate their businesses, including how clinical trials are conducted. Most clinical trial research organizations have tried to adapt by tweaking a platform here, adding a new app there, but this has only yielded patchwork systems of sites, spreadsheets and dashboards that further burden the process.

Read More

Enabling Active Pharma Ingredients for Batch Balancing and Integration to SAP EWM

Article | April 6, 2020

Batch and its Classification system are two most potent weapons used in Chemical, Pharma or Medical life science industry to record the potency of a batch or technically called as Active Pharma Ingredients(API). These material consist of one or more active ingredients, concentrates, carrier materials, or impurities, and so on. The potency of the active ingredients varies from batch to batch. The active ingredient is the substance of greatest interest in the bill of materials, the proportion of which may vary from batch to batch. Therefore, during creation of a process order, the system must be able to select and adjust the batches needed to obtain the required amount of active ingredient. Take an example of a drug hydroxychloroquine which is used as potent weapon to fight COVID-19. This drug is manufactured by using API, however, the Potency of this API material vary from batch to batch. To map this kind of requirement in SAP ERP, SAP calls it as Material Quantity Calculation.

Read More

Global Antiviral Drugs Market Growth: Is Antiviral Drug the Best Coronavirus Treatment?

Article | April 9, 2020

The global antiviral drugs market has witnessed a rapid surge in demand due to the ongoing Covid-19 pandemic worldwide. So is antiviral drug the best coronavirus treatment? It is still too early to have that conclusion as many medical research and clinical trials are still trying to find the effectiveness and potential side effects of using antiviral drugs to treat coronavirus. But experts believe that antiviral drug might be the best hope for reduce the coronavirus transmission around the world at this stage. However, due to the current difficult situation of the supply chain in many lockdown countries and regions, there is a global shortage on the antiviral drugs supply. With researchers and manufacturers working hard to find and provide effective coronavirus treatment, it is expected that the global antiviral drugs market will have a significant growth over the near future. Antiviral drugs are a type of medication used specifically for treating viral infections, such as human immunodeficiency virus (HIV), hepatitis, and influenza.

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Spotlight

Merck Consumer Health Care

Merck is a global pharmaceutical and chemical company with a history that began in 1668, and a future shaped by around 40,000 employees in 64 countries. With the acquisition of Millipore in July 2010, a global leader in the life science tools market, pro forma revenues totaled around EUR 8.9 billion in 2009. Innovations made possible by entrepreneurial employees characterize the company’s success. Merck's operating activities are combined under the umbrella of Merck KGaA, in which the Merck family indirectly holds an interest of approximately 70%. The remaining 30% is publicly traded.

Events